Roivant Sciences is a privately owned biopharmaceutical company that currently owns 57.5% of the outstanding shares of Immunovant. In a Securities and Exchange Commission (SEC) filing submitted today, Roivant expressed the desire to buy out the 42.5% stake in Immunovant it currently does not own. Roivant did not say how much the proposed transaction would be worth.